The engineered human anti-tumor necrosis factor-alpha antibody CDP571 inhibits inflammatory pathways but not T cell activation in patients with rheumatoid arthritis.
Choy, E H
The engineered human anti-tumor necrosis factor-alpha antibody CDP571 inhibits inflammatory pathways but not T cell activation in patients with rheumatoid arthritis. [electronic resource] - The Journal of rheumatology Nov 1999 - 2310-7 p. digital
Publication Type: Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
0315-162X
Antibodies--adverse effects
Arthritis, Rheumatoid--immunology
Autoantibodies--analysis
CD4 Antigens--blood
Collagen--urine
Collagen Type I
Female
Humans
Interleukin-6--blood
Leukocytes, Mononuclear--physiology
Lymphocyte Activation
Male
Matrix Metalloproteinase 3--blood
Middle Aged
Peptides--urine
Phenotype
Receptors, Interleukin-2--blood
Recombinant Proteins--immunology
T-Lymphocytes--drug effects
Tumor Necrosis Factor-alpha--immunology
The engineered human anti-tumor necrosis factor-alpha antibody CDP571 inhibits inflammatory pathways but not T cell activation in patients with rheumatoid arthritis. [electronic resource] - The Journal of rheumatology Nov 1999 - 2310-7 p. digital
Publication Type: Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
0315-162X
Antibodies--adverse effects
Arthritis, Rheumatoid--immunology
Autoantibodies--analysis
CD4 Antigens--blood
Collagen--urine
Collagen Type I
Female
Humans
Interleukin-6--blood
Leukocytes, Mononuclear--physiology
Lymphocyte Activation
Male
Matrix Metalloproteinase 3--blood
Middle Aged
Peptides--urine
Phenotype
Receptors, Interleukin-2--blood
Recombinant Proteins--immunology
T-Lymphocytes--drug effects
Tumor Necrosis Factor-alpha--immunology